Halozyme Therapeutics Inc. (HALO)
Time for HALO Sectors & ETFs?
HALO stocks are gaining favor as investors rotate toward tangible assets and AI-resistant businesses. Here are ETFs to play the trend.
Time to Buy Wide Moat & HALO ETFs?
Wall Street is caught in the midst of shifting geopolitical stances of the United States and Iran, chances of higher global inflation, weak U.S. jobs data, the possibility of stagflation in the U.S. economy, and the Fed's likely dilemma in fixing the monetary policy amid a weakening labor market and accelerating inflation. Also, the occasional selloffs in the red-hot artificial intelligence (AI) space have been a steady concern.
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?
Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock?
Sky Harbour: The Ultimate HALO Investment Taking Flight
Sky Harbour is building a national network of private aviation campuses on some of America's most irreplaceable airport real estate. The company's business model fits squarely within my HALO framework: Heavy Assets, Low Obsolescence. Airport land is among the most supply-constrained infrastructure assets in the United States.
Anti-AI Investing: The HALO Moat
I focus on HALO investing: Heavy Assets, Low Obsolescence - owning irreplaceable physical assets with durable moats against technological disruption. Top recommendations include American Tower, Brookfield Infrastructure, Prologis, Rexford Industrial, Lineage, Americold, VICI Properties, and Lamar Advertising. AMT, COLD, and VICI currently offer attractive entry points based on discounted multiples, robust dividend yields, and resilient, monopoly-like asset bases.
Implied Volatility Surging for Halozyme Therapeutics Stock Options
Investors need to pay close attention to HALO stock based on the movements in the options market lately.
Halozyme Therapeutics: Royalty King
Halozyme Therapeutics is delivering strong shareholder value, driven by robust royalty growth and disciplined capital allocation. HALO posted a double beat on Q1 2026 earnings, reaffirmed 2026–2028 guidance, and announced a new $1 billion share repurchase program. HALO trades at a significant discount to historical and sector valuations, despite maintaining >75% gross margins and strong free cash flow.
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript
Halozyme Therapeutics, Inc. (HALO) Q1 2026 Earnings Call Transcript
Halozyme Therapeutics Q1 Earnings Call Highlights
Halozyme Therapeutics NASDAQ: HALO reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced a new $1 billion share repurchase authorization.
Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.6 per share, beating the Zacks Consensus Estimate of $1.54 per share. This compares to earnings of $1.11 per share a year ago.
